secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001664710-25-000052
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros ends PAH program, cuts 45% of staff, expects $17M annual savings
----------------------------------------------------------------------

- TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.
- Workforce reduced ~45% to 85 employees; one-time severance charges of ~$3.2M in Q2 2025.
- Annualized cost savings of ~$17M expected; restructuring substantially complete by Q4 2025.
- Strategic alternatives review ongoing; preliminary update to be provided by June 9, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/0001664710-25-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/kros-20250528.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer